Similar Articles
571 Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
572 Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma
573 Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review
574 Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
575 High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation
576 Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges
577 Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic
578 Imaging presentation and postoperative recurrence of peliosis hepatis: A case report
579 Application of radiomics in hepatocellular carcinoma: A review
580 Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA